Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta–(Newsfile Corp. – September 15, 2022) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (« Hemostemix » or the « Company ») is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board.
Since 2019, Dr. Johannes Grillari is the director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma) – the Research Center in cooperation with AUVA, Vienna, Austria which is the central research unit of seven trauma centers and four rehabilitation centers with a strong focus on tissue regeneration.
In his research, Dr. Grillari focuses on improving our understanding of the molecular and physiological changes that occur during cellular aging, their impact on organismal aging and tissue regeneration, specifically in skin and bone. In addition, he is interested in engineering of mammalian cells to establish relevant and standardizable cell model systems and cell factories.
Johannes Grillari has graduated in Biotechnology at the University of Natural Resources and Life Sciences Vienna (BOKU), where he completed his PhD in the field of cell aging in 1999. He has founded and has been leading research groups on cellular aging and tissue regeneration since then. He has published more than 200 peer reviewed articles, is co-inventor of 15 patents, a co-founder of 4 companies, and has been invited speaker to more than 150 international conferences and departmental seminars. He has received several awards including the Walter-Doberauer award for aging research.
« I have worked in the field of stem cell science and aging since 2000. ACP-01 is unique and its study results results are very promising, » said Dr. Grillari. « I look forward to working with the other members of the SAB in support of the Company’s contribution to science and commercialization goals, » said Dr. Grillari.
« As one of Europe’s most well-regarded cell aging scientist, Dr. Grillari is a great addition to our SAB team, as he enables us to bridge to Europe. We are delighted to welcome Dr. Grillari to our SAB, and I very much look forward to his counsel, » stated Thomas Smeenk, CEO.
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: email@example.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains « forward-looking information » within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, the Phase II Clinical Trial results, the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the « Litigation« ); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix’s operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.